Related Experiment Videos
Comparative effects of loratadine and terfenadine on cardiac K+ channels
1Department of Pharmacology, Georgetown University Medical Center, Washington, DC 20007, U.S.A.
Abstract:
Nonsedating H1-receptor antagonists appear to have wide and variable effects on the QT interval, mediated through modulation of cardiac K+ channels. By using the whole-cell patch-clamp technique, we examined the effects of terfenadine, loratadine, and descarboethoxyloratadine on a large family of K+ channels in ventricular myocytes and in Xenopus oocytes expressing the HERG delayed rectifier. The channels studied included the inward rectifier (I(Kl)) of rat and guinea pig, the transient outward K+ current (I(to)) of rat, the maintained K+ current (I(ped)) of rat, and the delayed rectifier K+ channels (I(Ks) and I(Kr)) of guinea pig myocytes. Loratadine and descarboethoxyloratadine, at therapeutic concentrations (30 to 100 nM), had no measurable effect on any one of the five types of K+ channels studied. At higher concentrations, 0.3 to 1.0 microM, only terfenadine had a significant suppressive effect on I(Kl) and delayed rectifier K+ channels, I(Kr) and I(Ks). At higher concentrations (1 to 2.5 microM), there were marked differences in the ability of the three drugs to suppress the five K+ channels. Generally, terfenadine was the most and loratadine, the least effective blocker of all K+ channels examined. The most susceptible K+ channels were the delayed rectifier channels (I(Ks) and I(Kr)) in guinea pig and I(ped) in rat myocytes. Comparative effects of loratadine and terfenadine examined on the I(Kr) channel (HERG) expressed in Xenopus oocytes suggest much higher affinity of this channel to terfenadine, such that 1 microM terfenadine completely suppressed the current, whereas loratadine had little or no effect. The preferential suppressive effect of terfenadine on the expressed HERG channel was consistent with data obtained on I(Kr) in isolated guinea pig ventricular myocytes. The strong suppressive effect of terfenadine, noted particularly on the I(Kr) and to a lesser extent on I(to), I(Kl), and I(Ks), may be the cause of the reported incidence of QT prolongation and arrhythmogenesis. The absence of significant effect of loratadine and descarboethoxyloratadine, especially on I(Kr), I(to), I(ped), and I(Kl), even at 100 x highest plasma concentrations achieved, may explain the absence of significant reports of QT prolongation and arrhythmogenesis by the latter drugs.
Insights
Terfenadine significantly blocks cardiac potassium channels, potentially causing QT prolongation. Loratadine and descarboethoxyloratadine show minimal effects on these channels, explaining their lower risk of cardiac events.
Area of Science:
- Pharmacology
- Cardiovascular Physiology
- Molecular Biology
Background:
- Nonsedating H1-receptor antagonists can affect the QT interval via cardiac K+ channel modulation.
- Understanding these interactions is crucial for drug safety.
Purpose of the Study:
- To investigate the effects of terfenadine, loratadine, and descarboethoxyloratadine on various cardiac K+ channels.
- To determine the molecular basis for observed differences in QT interval effects.
Main Methods:
- Whole-cell patch-clamp technique on ventricular myocytes and Xenopus oocytes.
- Assessed effects on inward rectifier (I(Kl)), transient outward (I(to)), maintained (I(ped)), and delayed rectifier (I(Ks), I(Kr)) K+ channels.
- Utilized therapeutic and higher drug concentrations.
Main Results:
- Terfenadine significantly suppressed I(Kl), I(Kr), and I(Ks) at higher concentrations.
- Loratadine and descarboethoxyloratadine showed no significant effects on any K+ channels at therapeutic concentrations.
- Terfenadine demonstrated a higher affinity for the HERG (I(Kr)) channel compared to loratadine.
Conclusions:
- Terfenadine's potent blockade of cardiac K+ channels, especially I(Kr), likely contributes to QT prolongation and arrhythmogenesis.
- Loratadine and descarboethoxyloratadine's lack of significant K+ channel inhibition suggests a safer cardiac profile.